Samantha Podrebarac
Educator and spiritual care practitioner at the NYU Center for Psychedelic Medicine
Data updated
Research Footprint
Samantha Podrebarac appears in 5 tracked papers (2018–2024), most studied alongside Psilocybin and Ayahuasca, across Alcohol Use Disorder (AUD), Substance Use Disorders (SUD) and Interpersonal Functioning & Social Connectedness.
Most-cited paper: Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (644 citations).
Frequent co-authors: Michael Bogenschutz, Susan Mennenga and Lindsey Owens.
Background & Research
Samantha Podrebarac is a spiritual care practitioner trained in spiritual healing and interfaith chaplaincy. Public profiles describe her as having worked with the NYU Center for Psychedelic Medicine on psilocybin-assisted psychotherapy trials for alcohol dependence and existential distress in cancer. She also offers spiritual healing and meditation support in psychedelic preparation and integration contexts.
Key Impact
She contributed to multiple early psychedelic-assisted psychotherapy studies on psilocybin for alcohol use disorder and cancer-related experiences, helping document patient, spiritual, and clinical outcomes.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Samantha Podrebarac is associated with.
NYU Center for Psychedelic Medicine
NYU Langone Health’s Center for Psychedelic Medicine (NYU CPM) conducts health-focused translational research, education, and training on the therapeutic use of psychedelic drugs across psychiatry, medicine, and preclinical science. It supports clinical trials and a research training program to develop investigators and clinicians in the field.
View stakeholder →Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →